VIDEO: Lutetium-PSMA-617 trials ask questions about patient selection

ByDavid Statman

In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses results from studies covering lutetium-PSMA-617, two of which were major features in the prostate cancer section at ASCO Annual Meeting.

After touching on the data from the studies, Dorff examines another critical facet of the two studies: what they have to tell us on how to select patients for the recently FDA-approved treatment.

“I think a lot of us are looking to [the questions the studies are asking], namely which features of the PSMA PET can we use to select patients who are most likely to benefit?” Dorff said.

References:

Hofman M, et al. TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Chi K, et al. ASCO GU 2022: Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with mCRPC. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Dorff reports consulting for Astellas, AstraZeneca, Janssen, Pfizer and Seagen.

Take Homes in Prostate Cancer

Read more

VIDEO: Lutetium-PSMA-617 trials ask questions about patient selection

References:

Related Content